RxDoctor Payments Data

James Lilly, MD

Gastroenterology · New Orleans, LANPI 1003819350

Payments from drug & device makers

$6,222in general payments, 2019–2025

Across 423 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$546
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$460
  • Pfizer$305
  • Bristol Myers Squibb$292
  • Sanofi$285
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$6,19199%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,222 in reported general payments places this provider in the 60th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$86,736
Medicare patients
338
Services billed
652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase28$66,329
LinzessLinaclotide67$56,688
VoqueznaVonoprazan Fumarate16$11,999
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag71$8,953
SutabSod Sulf/Pot Chloride/Mag Sulf35$5,776
ClenpiqSod Picosulf/Mag Ox/Citric Ac28$4,635
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates42$2,634
Pantoprazole Sodium348$2,123
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C12$1,646
Budesonide DrBudesonide31$1,611
Omeprazole70$1,358
Ursodiol14$1,308
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl76$1,230
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl61$1,000
Esomeprazole Magnesium27$963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$47$66,32928 claims
AbbVieLinzess$2,542$56,68867 claims
Braintree Laboratories, Inc.Suflave, Sutab$12$14,728106 claims
Phathom Pharmaceuticals, Inc.Voquezna$83$11,99916 claims
Ferring Pharmaceuticals Inc.Clenpiq$74$4,63528 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$460$1,64612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →